{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:25:08Z","timestamp":1788830708368,"version":"build-2803163510"},"reference-count":103,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related death worldwide, and first-line systemic treatment has shifted toward immune checkpoint inhibitor (ICI)-based combinations. Response is heterogeneous, and mechanistic interpretation has lagged behind clinical practice, leaving open the question of why some tumors respond while others do not. This review uses the cancer immunity cycle as an HCC-specific scaffold to map where anti-tumor immunity fails\u2014across priming, trafficking, suppressive myeloid or stromal, and metabolic-hypoxic barriers\u2014and interpret combination strategies and resistance through the dominant barrier each tumor presents. ICI monotherapy rescues only specific failure points within the cycle. Combination regimens may be more effective when they are matched to one or more dominant barriers, whereas response may fail when the selected partner addresses only a secondary barrier while the dominant ecological constraint remains intact. Resistance can be similarly organized into tumor cell autonomous, microenvironmental, treatment-induced, and etiology-specific layers, with disease etiology shaping both baseline immune ecology and therapy-context vulnerability. A mechanism-based, biomarker-guided, and etiology-aware framework may help move the field from broad empiricism toward precision immunotherapy, but it should be viewed as a conceptual and translational organizing model that requires prospective testing in biomarker-stratified studies.<\/jats:p>","DOI":"10.3390\/cells15121097","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:58:38Z","timestamp":1781661518000},"page":"1097","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy and Hepatocellular Carcinoma: From Tumor-Immune Cell Interactions to Rational Therapeutic Strategies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2899-4030","authenticated-orcid":false,"given":"Kizuki","family":"Yuza","sequence":"first","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA"},{"name":"Department of Gastroenterological Surgery, Yokohama City University, Yokohama 236-0004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global Trends in Hepatocellular Carcinoma Epidemiology: Implications for Screening, Prevention and Therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-immunol-051116-052415","article-title":"Immune Responses in the Liver","volume":"36","author":"Kubes","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH Limits Anti-Tumour Surveillance in Immunotherapy-Treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (CheckMate 9DW): An Open-Label, Randomised, Phase 3 Trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-019-1373-2","article-title":"A Human Liver Cell Atlas Reveals Heterogeneity and Epithelial Progenitors","volume":"572","author":"Aizarani","year":"2019","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T Cell Exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T Cells That Provide the Proliferative Burst after PD-1 Therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of Exhausted CD8+ T Cells Differentially Mediate Tumor Control and Respond to Checkpoint Blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mikulak, J., Bruni, E., Oriolo, F., Di Vito, C., and Mavilio, D. (2019). Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00946"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hep.30347","article-title":"Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma","volume":"70","author":"Sun","year":"2019","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical Role for CD103(+)\/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral Dendritic Cell-CD4+ T Helper Cell Niches Enable CD8+ T Cell Differentiation Following PD-1 Blockade in Hepatocellular Carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-Associated Macrophages as Treatment Targets in Oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as Tools and Targets in Cancer Therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting Macrophages: Therapeutic Approaches in Cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","article-title":"Onco-Fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma","volume":"183","author":"Sharma","year":"2020","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a Tumour Immune Barrier in the HCC Microenvironment That Determines the Efficacy of Immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Shi, G., Xiao, Y., Li, Z., Qiu, Y., Zhou, Y., Zhang, J., Li, W., He, L., Xie, F., and Cao, H. (2026). CD48 Is a Novel Immune Checkpoint on Tumour-Associated Macrophages in Hepatocellular Carcinoma. Gut, online ahead of print.","DOI":"10.1136\/gutjnl-2025-336744"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-Derived Suppressor Cells Coming of Age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-Derived Suppressor Cells in the Era of Increasing Myeloid Cell Diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4(+)CD25(+)Foxp3(+) T Cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hep.26013","article-title":"Activated Tumor-Infiltrating CD4+ Regulatory T Cells Restrain Antitumor Immunity in Patients with Primary or Metastatic Liver Cancer","volume":"57","author":"Verhoef","year":"2013","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased Regulatory T Cells Correlate with CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-Tumoral Tertiary Lymphoid Structures Are Associated with a Low Risk of Early Recurrence of Hepatocellular Carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus Ipilimumab for Potentially Resectable Hepatocellular Carcinoma: Long-Term Efficacy and Biomarker Exploration","volume":"84","author":"Lin","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","article-title":"Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology","volume":"9","author":"Semenza","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial Stress Induced by Continuous Stimulation under Hypoxia Rapidly Drives T Cell Exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The Ectonucleotidases CD39 and CD73: Novel Checkpoint Inhibitor Targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nri.2016.4","article-title":"Purinergic Regulation of the Immune System","volume":"16","author":"Cekic","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the Fibrotic Niche of Human Liver Cirrhosis at Single-Cell Level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","article-title":"Presence of Onco-Fetal Neighborhoods in Hepatocellular Carcinoma Is Associated with Relapse and Response to Immunotherapy","volume":"5","author":"Li","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-018-06318-7","article-title":"Single Cell RNA Sequencing of Human Liver Reveals Distinct Intrahepatic Macrophage Populations","volume":"9","author":"MacParland","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.immuni.2019.08.017","article-title":"Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the Kupffer Cell Identity on Monocytes Colonizing the Liver Macrophage Niche","volume":"51","author":"Bonnardel","year":"2019","journal-title":"Immunity"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.immuni.2019.09.002","article-title":"Liver-Derived Signals Sequentially Reprogram Myeloid Enhancers to Initiate and Maintain Kupffer Cell Identity","volume":"51","author":"Sakai","year":"2019","journal-title":"Immunity"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eaau0964","DOI":"10.1126\/science.aau0964","article-title":"Two Distinct Interstitial Macrophage Populations Coexist across Tissues in Specific Subtissular Niches","volume":"363","author":"Chakarov","year":"2019","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct Populations of Inflammatory Fibroblasts and Myofibroblasts in Pancreatic Cancer","volume":"214","author":"Biffi","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e008721","DOI":"10.1136\/jitc-2023-008721","article-title":"POSTN+ Cancer-Associated Fibroblasts Determine the Efficacy of Immunotherapy in Hepatocellular Carcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"CXCL12+ Tumor-Associated Endothelial Cells Promote Immune Resistance in Hepatocellular Carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-Specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for Hepatocellular Carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of Cancer Immunity and the Cancer-Immune Set Point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and Neoadjuvant Immunotherapies in Hepatocellular Carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Campani, C., Galvanin, C., Shim, J.H., Bouattour, M., Touchefeu, Y., Delhoume, V., Rosmorduc, O., Pascale, A., An, J., and Lee, H.C. (Clin. Gastroenterol. Hepatol., 2025). The \u201cA-B-C\u201d Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab\/Bevacizumab, Clin. Gastroenterol. Hepatol., in press.","DOI":"10.1016\/S0168-8278(25)01331-5"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-Cell RNA Sequencing-Derived Signatures Define Response Patterns to Atezolizumab + Bevacizumab in Advanced Hepatocellular Carcinoma","volume":"82","author":"Cappuyns","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/gutjnl-2024-332837","article-title":"Spatial Single-Cell Profiling and Neighbourhood Analysis Reveal the Determinants of Immune Architecture Connected to Checkpoint Inhibitor Therapy Outcome in Hepatocellular Carcinoma","volume":"74","author":"Wischer","year":"2025","journal-title":"Gut"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting Mitochondrial Dysfunction Can Restore Antiviral Activity of Exhausted HBV-Specific CD8 T Cells in Chronic Hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.12.010","article-title":"Immune Responses to HCV and Other Hepatitis Viruses","volume":"40","author":"Park","year":"2014","journal-title":"Immunity"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular Characterisation of Hepatocellular Carcinoma in Patients with Non-Alcoholic Steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e0516","DOI":"10.1097\/HC9.0000000000000516","article-title":"The Immune Microenvironment of Steatotic Hepatocellular Carcinoma: Current Findings and Future Prospects","volume":"8","author":"Cheu","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular Carcinoma in the Setting of Alcohol-Related Liver Disease","volume":"70","author":"Nahon","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrgastro.2017.72","article-title":"The Gut Microbiome and Liver Cancer: Mechanisms and Clinical Translation","volume":"14","author":"Yu","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","article-title":"Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial","volume":"41","author":"Qin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated Efficacy and Safety Data from IMbrave150: Atezolizumab plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus Rivoceranib versus Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (CARES-310): Final Analysis of a Randomised, Open-Label, International, Phase 3 Study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative Nivolumab Monotherapy versus Nivolumab plus Ipilimumab in Resectable Hepatocellular Carcinoma: A Randomised, Open-Label, Phase 2 Trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus Bevacizumab versus Active Surveillance in Patients with Resected or Ablated High-Risk Hepatocellular Carcinoma (IMbrave050): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","article-title":"Updated Data from IMbrave050: Adjuvant Atezolizumab plus Bevacizumab for High-Risk Hepatocellular Carcinoma","volume":"84","author":"Yopp","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus Atezolizumab versus Sorafenib for Advanced Hepatocellular Carcinoma (COSMIC-312): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus Pembrolizumab versus Lenvatinib plus Placebo for Advanced Hepatocellular Carcinoma (LEAP-002): A Randomised, Double-Blind, Phase 3 Trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Oura, K., Morishita, A., Tadokoro, T., Fujita, K., Tani, J., and Kobara, H. (2024). Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413590"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/a-2334-8311","article-title":"Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?","volume":"44","author":"Werner","year":"2024","journal-title":"Semin. Liver Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","article-title":"Combination Immunotherapy in Hepatocellular Carcinoma: Synergies among Immune Checkpoints, TKIs, and Chemotherapy","volume":"18","author":"Dai","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"101664","DOI":"10.1016\/j.jhepr.2025.101664","article-title":"Impact of LEAP-012 and EMERALD-1 in the Management of HCC","volume":"8","author":"Singal","year":"2026","journal-title":"JHEP Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without Bevacizumab with Transarterial Chemoembolisation in Hepatocellular Carcinoma (EMERALD-1): A Multiregional, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial Chemoembolisation Combined with Lenvatinib plus Pembrolizumab versus Dual Placebo for Unresectable, Non-Metastatic Hepatocellular Carcinoma (LEAP-012): A Multicentre, Randomised, Double-Blind, Phase 3 Study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"101658","DOI":"10.1016\/j.jhepr.2025.101658","article-title":"Pembrolizumab and Stereotactic Body Radiotherapy Combined in Advanced Hepatocellular Carcinoma Post Sorafenib\u2014A Phase II Trial (PEMRAD)","volume":"8","author":"Mesci","year":"2026","journal-title":"JHEP Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology\/RTOG 1112 Phase 3 Randomized Clinical Trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma","volume":"9","author":"Bresnahan","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","article-title":"Biomarkers for Immunotherapy of Hepatocellular Carcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","article-title":"Immunosuppressive Tumor Microenvironment in the Progression, Metastasis, and Therapy of Hepatocellular Carcinoma: From Bench to Bedside","volume":"13","author":"Yin","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"101130","DOI":"10.1016\/j.jhepr.2024.101130","article-title":"Immunotherapy for Hepatocellular Carcinoma","volume":"6","author":"Childs","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Yizhak","year":"2018","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.cell.2018.09.030","article-title":"High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy","volume":"175","author":"Gubin","year":"2018","journal-title":"Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhep.2025.08.018","article-title":"New Targets and New Drugs for Hepatobiliary Cancers","volume":"84","author":"Chan","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Yang, H., Liu, Y., Zhang, N., Tao, F., and Yin, G. (2024). Therapeutic Advances in Hepatocellular Carcinoma: An Update from the 2024 ASCO Annual Meeting. Front Oncol., 14.","DOI":"10.3389\/fonc.2024.1453412"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"17588359251323199","DOI":"10.1177\/17588359251323199","article-title":"Future Perspectives on Immunotherapy for Hepatocellular Carcinoma","volume":"17","author":"Chan","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41416-025-03296-8","article-title":"Circulating Tumour DNA for a Minimal Residual Disease Assessment and Recurrence Risk in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"134","author":"Buonopane","year":"2026","journal-title":"Br. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e2400934","DOI":"10.1200\/PO-24-00934","article-title":"Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma","volume":"9","author":"Abdelrahim","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102908","DOI":"10.1016\/j.ctrv.2025.102908","article-title":"Circulating Blood Biomarkers for Minimal Residual Disease in Hepatocellular Carcinoma: A Systematic Review","volume":"135","author":"Galli","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut Microbiome Affects the Response to Anti-PD-1 Immunotherapy in Patients with Hepatocellular Carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/12\/1097\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:18:54Z","timestamp":1781662734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/12\/1097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":103,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cells15121097"],"URL":"https:\/\/doi.org\/10.3390\/cells15121097","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}